ClinicalTrials.gg
RecruitingNCT07005570Updated Nov 10, 2026

Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer (SPARK)

A Phase 2 interventional study of Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab and Short-course radiotherapy followed by sequential chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer, sponsored by Dechang Diao. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Dechang Diao · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 10, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
203rd of 373
86 · median 100
Started
2025
with 68 others
Phase 2
155 of 463
95 open now
Primary completion
2031-12
later than 260 of 266 live
Registered
363rd of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 203rd largest by planned enrollment of the 373 interventional ones that give a count, is one of 69 that started in 2025, is one of 155 in phase 2, reaches primary completion later than 260 of the 266 other live ones, and was the 363rd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Safety and efficacy of Short-Course Radiotherapy Followed by Sequential Chemotherapy with or without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.

Complete Response (CR) Rate of Short-Course Radiotherapy Followed by Sequential Chemotherapy with or without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer.

03

Conditions studied

  • pMMR/MSS Locally Advanced Rectal Cancer

Browse trials for

Keywords

  • PD-1 monoclonal antibody
  • VEGF monoclonal antibody
  • total neoadjuvant therapy (TNT)
  • pMMR/MSS locally advanced rectal cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily signed written form.
  2. Age ≥18 and ≤75 years at enrollment.
  3. (ECOG) performance status score of 0 or 1.
  4. >2 years.
  5. confirmed rectal adenocarcinoma.
  6. Tumor demonstrating pMMR (all four mismatch repair proteins-MSH1, MSH2, MSH6, and PMS2-positive by immunohistochemistry) or genetic testing confirming MSS (microsatellite stable).
  7. Clinical stage II-III rectal cancer (cT3-4NanyM0 or cTxN+M0) per AJCC 8th Edition TNM staging, assessed via high-resolution MRI ± endoscopic ultrasound/transrectal Doppler ultrasound. Tumor must be ≤12 cm from the anal verge by MRI.
  8. Pre-enrollment surgical evaluation by an attending surgeon confirming eligibility for curative-intent R0 resection.
  9. No prior systemic or local anti-cancer therapy for rectal cancer (radiotherapy, chemotherapy, immunotherapy, biologics, or small-molecule targeted therapy).
  10. Willingness to provide tumor tissue (archival or fresh biopsy) and peripheral blood samples for biomarker analysis during screening and study procedures.
  11. Adequate organ function.
  12. For women of (WOCBP):Negative urine or serum pregnancy test within 3 days prior to treatment (serum test required if urine result is inconclusive).Agreement to use highly effective (e.g., intrauterine device, hormonal implants) from screening until 120 days after last study treatment. Periodic abstinence and calendar-based methods are prohibited.
  13. The subject is willing and able to comply with scheduled visits, treatment regimens, laboratory tests, and other study requirements as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Suspected lesions or locally advanced unresectable disease regardless of stage.
  2. History of other within 5 years prior to enrollment, except those cured by local therapy (e.g., basal/squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the breast).
  3. Concurrent participation in another interventional clinical trial (observational or non-interventional studies allowed).
  4. Acute complications requiring emergency surgery (e.g., bowel obstruction, perforation, hemorrhage).
  5. Multiple primary rectal cancers.
  6. Prior pelvic/abdominal radiotherapy.
  7. Conditions impairing oral drug absorption (e.g., dysphagia, malabsorption syndrome).
  8. Prior systemic/local anti-tumor therapy for locally advanced rectal cancer (surgery, chemotherapy, radiotherapy, immunotherapy [/agonists, cell therapy], biologics, or targeted agents).
  9. Non-specific immunomodulators (e.g., interleukins, interferons) within 2 weeks or anti-tumor herbal medicines within 1 week prior to treatment.
  10. Active disease requiring systemic (e.g., >10 mg/day prednisone equivalent) within 2 years (hormone replacement allowed).
  11. History of non-infectious pneumonitis or interstitial lung disease requiring steroids.
  12. Bleeding diathesis/coagulopathy or chronic anticoagulation (e.g., CHADS2 score ≥2 for atrial fibrillation).
  13. Uncontrolled comorbidities (e.g., decompensated cirrhosis, nephrotic syndrome, peptic ulcers) or psychiatric disorders affecting consent/study compliance.
  14. Cardiac history:Myocarditis/cardiomyopathy/malignant arrhythmias.Unstable angina/CHF within 12 months.Arterial thromboembolism within 6 months (e.g., stroke, ).Grade ≥3 venous thromboembolism ( v5.0).Uncontrolled hypertension (SBP ≥160 mmHg/DBP ≥100 mmHg).
  15. Active inflammatory bowel disease (Crohn's/ulcerative colitis) or chronic diarrhea.

16Active severe infection requiring hospitalization/systemic antibiotics within 4 weeks (excluding / antivirals).

17.Major surgery/trauma within 30 days or minor procedures within 3 days (excluding PICC placement).

18.Immunodeficiency (-positive, chronic immunosuppressants). 19.Active tuberculosis (confirmed by sputum/X-ray) or syphilis. 20.Prior allogeneic organ/stem cell transplantation. 21.Active hepatitis:HBV: HBsAg+ with HBV-DNA >1000 copies/mL (200 IU/mL) without antiviral therapy.HCV: Anti-HCV+ with detectable HCV-RNA.

22. within 30 days or planned during study. 23. to study drugs/monoclonal antibodies. 24.Substance abuse or psychiatric disorders compromising compliance. 25.Pregnancy/lactation. 26.Conditions confounding efficacy/safety assessments or limiting survival evaluation (e.g., leukemoid reaction [WBC >20×10⁹/L], cachexia [>10% weight loss in 3 months], ≤18).

27.Other conditions deemed inappropriate by investigators.

Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Control group

    Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.

    Other: Short-course radiotherapy followed by sequential chemotherapy

  • Experimental
    Experimental group

    Short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.

    Other: Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab

Interventions

  • OtherShort-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab

    Short-course radiotherapy → PD-1 monoclonal antibody and bevacizumab combined with CAPOX regimen chemotherapy (4 cycles) → PD-1 monoclonal antibody combined with CAPOX regimen chemotherapy (2 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.

  • OtherShort-course radiotherapy followed by sequential chemotherapy

    Short-course radiotherapy → CAPOX regimen chemotherapy (6 cycles) → undergo surgery or watch-and-wait strategy within 2-4 weeks after the last dose of capecitabine.

06

What researchers measure

Primary outcomes

  1. Complete Response Rate

    Defined as the proportion of subjects achieving pathological complete response (pCR) or clinical complete response (cCR) following neoadjuvant therapy. pCR is characterized by the absence of residual tumor in the resected primary tumor site and lymph nodes; cCR is defined as achieving ycT0N0 status according to the 2024 CWWD criteria.

    Time frame: cCR will be assessed 2-4 weeks after completion of TNT, with final clinical classification by 8 weeks after completion of TNT. pCR will be assessed 1 week after TME.

Secondary outcomes

  1. Pathological complete response rate

    Proportion of all randomised participants with no viable tumour in the resected primary tumour and all assessed regional lymph nodes (ypT0N0).

    Time frame: 1 week after TME.

  2. Clinical complete response rate

    Proportion of all randomised participants with confirmed cCR who enter watch-and-wait without total mesorectal excision in the primary-response assessment pathway. Digital rectal examination, contrast-enhanced pelvic MRI and endoscopy must all meet the prespecified cCR criteria.

    Time frame: cCR assessed at 2-4 weeks after TNT completion, with final clinical classification by 8 weeks after TNT completion.

  3. Tumour regression grade

    Distribution of primary-tumour regression grades among participants undergoing radical surgery, using the American Joint Committee on Cancer (AJCC) system. Grades 0, 1, 2 and 3 indicate complete, near-complete, partial, and poor or no response, respectively.

    Time frame: 1 week after TME.

  4. R0 resection rate

    Proportion of participants undergoing radical surgery with no macroscopic residual disease and microscopically negative proximal, distal and circumferential resection margins.

    Time frame: 1 week after TME.

  5. Sphincter preservation rate

    roportion of all randomised participants managed with watch-and-wait after confirmed cCR or undergoing sphincter-preserving surgery without a permanent stoma. A prophylactic temporary stoma is not a failure. An unreversed stoma determined to be permanent is a failure.

    Time frame: 1 year after completion of radical treatment. For participants undergoing total mesorectal excision, the surgery date is the reference date.

  6. Event-free survival

    Time from randomisation to the first objectively confirmed distant metastasis or local disease progression, unresectable disease or macroscopic residual disease at surgery (R2), local recurrence after surgery, or death from any cause.

    Time frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. EFS probabilities are assessed at 1, 2 and 3 years.

  7. Title: Overall survival

    Time from randomisation to death from any cause. Participants without a documented death are censored at the last date they were known to be alive.

    Time frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. Median OS and the 3-year OS probability are assessed.

  8. 3-year cumulative incidence of postoperative local recurrence

    Cumulative incidence of the first objectively confirmed local recurrence after surgery within 3 years after randomisation. Death before local recurrence is treated as a competing event.

    Time frame: From randomisation through 3 years.

  9. 3-year cumulative incidence of distant metastasis

    Cumulative incidence of first objectively confirmed distant metastasis, with death before metastasis treated as a competing event.

    Time frame: From randomisation through 3 years.

  10. Incidence and severity of adverse events

    Incidence and severity of adverse events, including clinically relevant laboratory abnormalities and perioperative events, among participants receiving any protocol treatment, reported by treatment received. Grading uses CTCAE v5.0, except late radiation toxicity, which uses RTOG/EORTC. Postoperative complications are summarised among surgical participants and graded using Clavien-Dindo.

    Time frame: AEs: first study treatment to 90 days after the last study-drug dose or 30 days after surgery, whichever is later. Postoperative complications: surgery through day 30.

Other outcomes

  1. Health-related quality of life

    EORTC QLQ-C30 and QLQ-CR29 domain and single-item scores, including changes from baseline.

    Time frame: Before first study treatment, 2 days before cycle 4 (21-day cycles), at TNT completion, then every 3 months for 2 years and every 6 months thereafter until study completion, with planned follow-up of at least 36 months after randomisation.

  2. Patient-reported symptomatic adverse events

    Scores for selected PRO-CTCAE symptom domains and attributes, using the official questionnaire with a 7-day recall period.

    Time frame: Every 3 weeks during treatment, starting on the first day of study treatment.

  3. Nutritional risk and status

    NRS 2002 screening results and scores, together with PG-SGA scores and global categories among participants undergoing that assessment. No PG-SGA score or category is assigned when assessment is not performed after a negative nutritional screen.

    Time frame: Baseline, before each systemic treatment cycle, at TNT completion, and before and 30 days after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2031, 79 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 79 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2027 → Dec 2031 and completion Dec 2027 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2025
First posted
Jun 5, 2025
StartActual
May 23, 2025
Primary completionEst.
Dec 31, 2031was Jul 2027
CompletionEst.
Dec 31, 2031was Dec 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2025→May 23, 2025
Nov 10, 2026
Primary completion
Jul 1, 2027→Dec 31, 2031
Nov 10, 2026
Study completion
Dec 1, 2027→Dec 31, 2031
Nov 10, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedComplete Response (CR) RateTime frame: 2-4week → cCR will be assessed 2-4 weeks after completion of TNT, with final clinical classification by 8 weeks after completion of TNT. pCR will be assessed 1 week after TME.
  • RemovedAdverse eventsTime frame: 2-4week
Nov 10, 2026
Secondary outcomes
13 added
What changed in the outcomes
  • AddedPathological complete response rateTime frame: 1 week after TME.
  • AddedClinical complete response rateTime frame: cCR assessed at 2-4 weeks after TNT completion, with final clinical classification by 8 weeks after TNT completion.
  • AddedTumour regression gradeTime frame: 1 week after TME.
  • AddedR0 resection rateTime frame: 1 week after TME.
  • AddedSphincter preservation rateTime frame: 1 year after completion of radical treatment. For participants undergoing total mesorectal excision, the surgery date is the reference date.
  • AddedEvent-free survivalTime frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. EFS probabilities are assessed at 1, 2 and 3 years.
  • AddedTitle: Overall survivalTime frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. Median OS and the 3-year OS probability are assessed.
  • Added3-year cumulative incidence of postoperative local recurrenceTime frame: From randomisation through 3 years.
  • Added3-year cumulative incidence of distant metastasisTime frame: From randomisation through 3 years.
  • AddedIncidence and severity of adverse eventsTime frame: AEs: first study treatment to 90 days after the last study-drug dose or 30 days after surgery, whichever is later. Postoperative complications: surgery through day 30.
  • Addedother outcomeHealth-related quality of lifeTime frame: Before first study treatment, 2 days before cycle 4 (21-day cycles), at TNT completion, then every 3 months for 2 years and every 6 months thereafter until study completion, with planned follow-up of at least 36 months after randomisation.
  • Addedother outcomePatient-reported symptomatic adverse eventsTime frame: Every 3 weeks during treatment, starting on the first day of study treatment.
  • Addedother outcomeNutritional risk and statusTime frame: Baseline, before each systemic treatment cycle, at TNT completion, and before and 30 days after surgery.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Start date May 1, 2025→May 23, 2025
    Primary completion Jul 1, 2027→Dec 31, 2031
    Study completion Dec 1, 2027→Dec 31, 2031
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedComplete Response (CR) RateTime frame: 2-4week → cCR will be assessed 2-4 weeks after completion of TNT, with final clinical classification by 8 weeks after completion of TNT. pCR will be assessed 1 week after TME.
    • RemovedAdverse eventsTime frame: 2-4week
    Secondary outcomes 13 added
    What changed in the outcomes
    • AddedPathological complete response rateTime frame: 1 week after TME.
    • AddedClinical complete response rateTime frame: cCR assessed at 2-4 weeks after TNT completion, with final clinical classification by 8 weeks after TNT completion.
    • AddedTumour regression gradeTime frame: 1 week after TME.
    • AddedR0 resection rateTime frame: 1 week after TME.
    • AddedSphincter preservation rateTime frame: 1 year after completion of radical treatment. For participants undergoing total mesorectal excision, the surgery date is the reference date.
    • AddedEvent-free survivalTime frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. EFS probabilities are assessed at 1, 2 and 3 years.
    • AddedTitle: Overall survivalTime frame: From randomisation to the final follow-up data cut-off, with planned follow-up of at least 36 months per participant. Median OS and the 3-year OS probability are assessed.
    • Added3-year cumulative incidence of postoperative local recurrenceTime frame: From randomisation through 3 years.
    • Added3-year cumulative incidence of distant metastasisTime frame: From randomisation through 3 years.
    • AddedIncidence and severity of adverse eventsTime frame: AEs: first study treatment to 90 days after the last study-drug dose or 30 days after surgery, whichever is later. Postoperative complications: surgery through day 30.
    • Addedother outcomeHealth-related quality of lifeTime frame: Before first study treatment, 2 days before cycle 4 (21-day cycles), at TNT completion, then every 3 months for 2 years and every 6 months thereafter until study completion, with planned follow-up of at least 36 months after randomisation.
    • Addedother outcomePatient-reported symptomatic adverse eventsTime frame: Every 3 weeks during treatment, starting on the first day of study treatment.
    • Addedother outcomeNutritional risk and statusTime frame: Baseline, before each systemic treatment cycle, at TNT completion, and before and 30 days after surgery.
    + 1 other change: design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07005570
Lead sponsor
Dechang Diao
Responsible party
Dechang Diao (PH.D., Sixth Affiliated Hospital, Sun Yat-sen University) — Sponsor-investigator
First posted
Jun 5, 2025
Start date
May 23, 2025
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Dechang Diao, Dr
Contact
diaodch3@mail.sysu.edu.cn
13416119782
Dechang Diao, Dr
study director · Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion